Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Early-Onset CRC: What Do We Know?

February 26th 2018

Treating Liver or Peritoneal Metastases in CRC

February 26th 2018

Managing Patients After Adjuvant Therapy

February 26th 2018

Duration of Adjuvant Therapy: CRC Subsets

February 26th 2018

Deciding on Adjuvant Therapy in CRC

February 26th 2018

Dr. Bekaii-Saab on the Impact of Regorafenib in CRC

February 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of regorafenib (Stivarga) on the treatment of patients with colorectal cancer (CRC).

Dr. Overman on Remaining Questions With Immunotherapy in CRC

February 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer.

Dr. Andre Discusses the Future of Immunotherapy in mCRC

February 20th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the future of immunotherapy for patients with metastatic colorectal cancer.

Biomarkers and Novel Approaches in CRC

February 17th 2018

Reverce Study: Outcomes and Impact

February 17th 2018

Sequencing of Therapy in Refractory mCRC

February 17th 2018

Management of Side Effects With TAS-102

February 17th 2018

Proactive Side Effect Management With Regorafenib

February 17th 2018

Clinical Implications of the ReDOS Findings

February 17th 2018

The Regorafenib Dose Optimization Study

February 17th 2018

Treatment Options in Refractory mCRC

February 17th 2018

Treatment Goals in Refractory mCRC

February 17th 2018

Expert Highlights Promising Research in mCRC and Other GI Cancers

February 17th 2018

Michael A. Morse, MD, discusses key trials that have broadened the treatment landscape of mCRC, and other ongoing developments in gastrointestinal cancers.

Lilly's Unique Reception Helps Attendees Step Into the Minds of People Living With GI Cancers

February 15th 2018

Lilly hosted an immersive and interactive reception during the 2018 Gastrointestinal Cancers Symposium entitled,

Dr. Bekaii-Saab on the Importance of the ReDOS Study in mCRC

February 14th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer (mCRC).